Development of the PARP inhibitor olaparib to generate new therapies for cancer patients

被引：0
|
作者：
O'Connor, Mark J. [1 ]
机构：
[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
来源：
MUTAGENESIS | 2012年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
32
引用
收藏
页码：799 / 799
页数：1
相关论文
共 50 条
  • [1] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Ying Chen
    Lei Zhang
    Quan Hao
    [J]. Archives of Gynecology and Obstetrics, 2013, 288 : 367 - 374
  • [2] Olaparib, PARP1 inhibitor in ovarian cancer
    Marchetti, Claudia
    Imperiale, Ludovica
    Gasparri, Maria Luisa
    Palaia, Innocenza
    Pignata, Sandro
    Boni, Terenzio
    Bellati, Filippo
    Panici, Pierluigi Benedetti
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
  • [3] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Chen, Ying
    Zhang, Lei
    Hao, Quan
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (02) : 367 - 374
  • [4] Tolerance and Toxicity of the PARP Inhibitor Olaparib in Older Women with Ovarian Cancer
    Dockery, L.
    Tew, W.
    Moore, K.
    Ding, K.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 197 - 198
  • [5] Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
    Osoegawa, Atsushi
    Gills, Joell J.
    Kawabata, Shigeru
    Sugio, Kenji
    Dennis, Phillip A.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [6] Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells
    Im, Seock-Ah
    Min, Ahrum
    Hur, Hyung-Seok
    Yoon, Young-Kwang
    Song, Sang Hyun
    Riches, Lucy
    Knights, Charlotte
    Han, Sae-Won
    Oh, Do-Youn
    Wombwell, Helen
    Kim, Tae-You
    Gu, Yi
    Lau, Alan
    Bang, Yung-Jue
    O'Connor, Mark
    [J]. CANCER RESEARCH, 2010, 70
  • [7] Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
    Osoegawa, Atsushi
    Gills, Joell J.
    Kawabata, Shigeru
    Dennis, Phillip A.
    [J]. ONCOTARGET, 2017, 8 (50) : 87044 - 87053
  • [8] Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations
    Hutchinson L.
    [J]. Nature Reviews Clinical Oncology, 2010, 7 (10) : 549 - 549
  • [9] Pediatric preclinical evaluation of the PARP inhibitor olaparib
    Norris, Robin E.
    Adamson, Peter C.
    Fox, Elizabeth
    [J]. CANCER RESEARCH, 2011, 71
  • [10] Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
    Gunderson, Camille C.
    Moore, Kathleen N.
    [J]. FUTURE ONCOLOGY, 2015, 11 (05) : 747 - 757
12345